Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07046312

Right Ventricular Strain in Detecting Subclinical Right Ventricular Systolic Dysfunction in Psoriatic Arthritis Patients: Relation to Serum Endostatin Level

The aim is to assess early right ventricular systolic dysfunction in psoriatic arthritis patients using RV strain echocardiography

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Previous studies evaluated RV strain for detection of subclinical RV affection due to PAH in systemic lupus erythematosus. However , to our knowledge , the study of RV strain and its possible association with serum endostatin to detect subclinical right ventricular systolic dysfunction and its relation to PAH in PsA patient is still a novel. Our aim is to assess early right ventricular systolic dysfunction in psoriatic arthritis patients using RV strain Echocardiography.

To evaluate serum endostatin as an objective biomarker for Pulmonary arterial hypertension.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Psoriatic arthritis patients according to CASPAR criteria
  • Psoriatic arthritis patients without overt cardiovascular symptoms
  • Patients with age between 20 to 50 years of age

Exclusion criteria

  • Other systemic autoimmune diseases
  • Patients with a history of known valvular disease, atrial fibrillation or any other arrhythmia , heart failure, ischemic cardiomyopathy severe obstructive pulmonary diseases and metabolic syndrome.
  • Patients with medical disorders as renal, congenital heart diseases, hematological disorders and cancer patients.
  • Patients taking certain drugs that have been confirmed to be risk factors for PAH such as appetite suppressant intake drugs (aminorex, fenfluramine derivatives and benfluorex) and chemotherapeutic agents.
  • Family history of myocardial infarction, cerebrovascular disease or sudden death before the age of 65y in females and 55 y in males.

Treatment and study plan

Primary outcomes

  1. Detecting subclinical right ventricular systolic dysfunction in PsA patients

    Time frame: Up to 24 months

    Detecting subclinical right ventricular systolic dysfunction in PsA using 2D strain transthoracic echo and its relation to serum endostatin level

Study contacts

Contact information is provided by the study sponsor or research team.

Dina Maamoun ElHadba, MSc Ain Shams University

CONTACT

[email protected]

01006780166

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jul 1, 2025
Registry last updated
Jul 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.